Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Borken – page 87

1 431 clinical trials in Borken, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Borken at a glance
1 431
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 431 trials in Borken

Open in trial search

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Study of Prednisolone and SPI-62 for Patients with Polymyalgia Rheumatica

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Brain neoplasm

Not recruiting

Safety Study of 5-Aminolevulinic Acid for Brain Tumor Surgery in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Borken

What the registry says about research in the country

01 Neuropathic Pain Research

Investigating innovative treatments for patients with diabetic polyneuropathy, focusing on new therapeutic approaches for chronic pain management.

  • Diabetic Neuropathy
  • Pain Management
  • Treatment Efficacy

Clinical evaluations of add-on treatments aim to improve quality of life for patients with chronic neuropathic conditions.

02 Trauma-Related Neuropathy

Studies examining treatment options for post-operative and traumatic peripheral neuropathy, with emphasis on chronic pain relief strategies.

  • Post-Surgical Pain
  • Trauma-Induced Neuropathy
  • Pain Relief Solutions

Research focused on developing effective therapeutic interventions for trauma-related chronic pain conditions.

03 Central Neuropathy Studies

Comprehensive research into central neuropathy of various origins, evaluating novel treatment approaches for chronic pain management.

  • Central Nervous System
  • Pain Treatment
  • Therapeutic Efficacy

Advanced clinical trials exploring innovative solutions for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigation of new therapeutic approaches for managing chronic back pain, focusing on treatment tolerability and effectiveness.

  • Back Pain Management
  • Pain Relief
  • Treatment Outcomes

Studies aimed at improving treatment options for patients suffering from persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.